Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications

The immune system responds to acute tissue damage after myocardial infarction (MI) and orchestrates healing and recovery of the heart. However, excessive inflammation may lead to additional tissue damage and fibrosis and exacerbate subsequent functional impairment, leading to heart failure. The appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Panahi, Mona, Vadgama, Nimai, Kuganesan, Mathun, Ng, Fu Siong, Sattler, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262592/
https://www.ncbi.nlm.nih.gov/pubmed/30384415
http://dx.doi.org/10.3390/jcm7110403
_version_ 1783375138947858432
author Panahi, Mona
Vadgama, Nimai
Kuganesan, Mathun
Ng, Fu Siong
Sattler, Susanne
author_facet Panahi, Mona
Vadgama, Nimai
Kuganesan, Mathun
Ng, Fu Siong
Sattler, Susanne
author_sort Panahi, Mona
collection PubMed
description The immune system responds to acute tissue damage after myocardial infarction (MI) and orchestrates healing and recovery of the heart. However, excessive inflammation may lead to additional tissue damage and fibrosis and exacerbate subsequent functional impairment, leading to heart failure. The appreciation of the immune system as a crucial factor after MI has led to a surge of clinical trials investigating the potential benefits of immunomodulatory agents previously used in hyper-inflammatory conditions, such as autoimmune disease. While the major goal of routine post-MI pharmacotherapy is to support heart function by ensuring appropriate blood pressure and cardiac output to meet the demands of the body, several drug classes also affect a range of immunological pathways and modulate the post-MI immune response, which is crucial to take into account when designing future immunomodulatory trials. This review outlines how routine post-MI pharmacotherapy affects the immune response and may thus influence post-MI outcomes and development towards heart failure. Current key drug classes are discussed, including platelet inhibitors, statins, β-blockers, and renin–angiotensin–aldosterone inhibitors.
format Online
Article
Text
id pubmed-6262592
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62625922018-12-03 Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications Panahi, Mona Vadgama, Nimai Kuganesan, Mathun Ng, Fu Siong Sattler, Susanne J Clin Med Review The immune system responds to acute tissue damage after myocardial infarction (MI) and orchestrates healing and recovery of the heart. However, excessive inflammation may lead to additional tissue damage and fibrosis and exacerbate subsequent functional impairment, leading to heart failure. The appreciation of the immune system as a crucial factor after MI has led to a surge of clinical trials investigating the potential benefits of immunomodulatory agents previously used in hyper-inflammatory conditions, such as autoimmune disease. While the major goal of routine post-MI pharmacotherapy is to support heart function by ensuring appropriate blood pressure and cardiac output to meet the demands of the body, several drug classes also affect a range of immunological pathways and modulate the post-MI immune response, which is crucial to take into account when designing future immunomodulatory trials. This review outlines how routine post-MI pharmacotherapy affects the immune response and may thus influence post-MI outcomes and development towards heart failure. Current key drug classes are discussed, including platelet inhibitors, statins, β-blockers, and renin–angiotensin–aldosterone inhibitors. MDPI 2018-10-31 /pmc/articles/PMC6262592/ /pubmed/30384415 http://dx.doi.org/10.3390/jcm7110403 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Panahi, Mona
Vadgama, Nimai
Kuganesan, Mathun
Ng, Fu Siong
Sattler, Susanne
Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications
title Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications
title_full Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications
title_fullStr Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications
title_full_unstemmed Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications
title_short Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications
title_sort immunopharmacology of post-myocardial infarction and heart failure medications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262592/
https://www.ncbi.nlm.nih.gov/pubmed/30384415
http://dx.doi.org/10.3390/jcm7110403
work_keys_str_mv AT panahimona immunopharmacologyofpostmyocardialinfarctionandheartfailuremedications
AT vadgamanimai immunopharmacologyofpostmyocardialinfarctionandheartfailuremedications
AT kuganesanmathun immunopharmacologyofpostmyocardialinfarctionandheartfailuremedications
AT ngfusiong immunopharmacologyofpostmyocardialinfarctionandheartfailuremedications
AT sattlersusanne immunopharmacologyofpostmyocardialinfarctionandheartfailuremedications